Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/10684
Title: Liver transplantation for hepatitis B: what is the best hepatitis B immune globulin/antiviral regimen?
Austin Authors: Angus, Peter W ;Patterson, Scott J 
Affiliation: Victorian Liver Transplant Unit, Austin Health, Heidelberg, Victoria, Australia
Issue Date: 1-Oct-2008
Publication information: Liver Transplantation : Official Publication of the American Association For the Study of Liver Diseases and the International Liver Transplantation Society; 14 Suppl 2(): S15-22
Abstract: 1. Prophylaxis using the combination of lamivudine and high-dose intravenous hepatitis B immunoglobulin (approximately 10,000 IU monthly) reduces the long-term risk of recurrence of hepatitis B in hepatitis B surface antigen-positive transplant recipients to 5% to 10%. However, this therapy is expensive and inconvenient for patients. 2. Recent studies have shown that similar results can be obtained, at far less cost, with much lower doses of intramuscular hepatitis B immune globulin (400-800 IU monthly) in combination with pretransplant and posttransplant lamivudine therapy. 3. The development of lamivudine resistance pre-transplant can lead to hepatic decompensation and increases the risk of posttransplant recurrence in patients receiving hepatitis B immune globulin/lamivudine prophylaxis. Newer nucleos(t)ide analogues with lower resistance rates such as entecavir, adefovir, and tenofovir should therefore replace lamivudine in hepatitis B prophylaxis. 4. Combination therapy with these newer agents and low-dose intramuscular hepatitis B immune globulin is likely to be the most cost effective hepatitis B immune globulin-containing regimen for the prevention of hepatitis B recurrence post-transplant. 5. Some form of hepatitis B virus prophylaxis needs be continued indefinitely post-transplant. However, the use of antivirals with very low rates of drug resistance will make it possible to stop hepatitis B immune globulin therapy in many patients currently receiving hepatitis B immune globulin/nucleos(t)ide combination therapy.
Gov't Doc #: 18825721
URI: http://ahro.austin.org.au/austinjspui/handle/1/10684
DOI: 10.1002/lt.21614
URL: https://pubmed.ncbi.nlm.nih.gov/18825721
Type: Journal Article
Subjects: Antiviral Agents.administration & dosage
Drug Therapy, Combination
Hepatitis B.drug therapy.surgery
Humans
Immunoglobulins, Intravenous.administration & dosage
Injections, Intramuscular
Lamivudine.administration & dosage
Liver Transplantation
Appears in Collections:Journal articles

Show full item record

Page view(s)

12
checked on Nov 28, 2022

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.